<DOC>
	<DOCNO>NCT01932658</DOCNO>
	<brief_summary>The purpose study evaluate safety potential clinical benefit lymphoablation follow autologous HSCT rescue therapy refractory Crohn 's disease</brief_summary>
	<brief_title>Autologous Hematopoietic Stem Cell Transplantation Crohn 's Disease Treatment</brief_title>
	<detailed_description>The treatment Crohn 's disease proven quite efficacious majority patient timely use combination therapy remission induction ( corticosteroid and/or biologics ) maintenance disease control ( immunosuppressive and/or biologics ) . However , proportion patient fail achieve complete long term disease control often require multiple intestinal surgery risk develop short bowel syndrome . Lymphoablation follow hematopoietic stem cell transplantation rescue immune system propose alternative strategy induce long term disease control high risk population . It demonstrate despite potential toxicity morbidity associate procedure , benefit-risk ratio favorable . Hence , propose offer HSCT select CD patient , study mechanism reduce T cell autoreactivity hopefully lead focused therapeutic approach future .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>1 . Age 7 50 year ( patient age 50 70 participate principal investigator discretion ) . 2 . Confirmed diagnosis active Crohn 's disease : 1 . Diagnosis Crohn 's disease base typical radiological appearance typical histology least 6 month prior screen . 2 . Active disease time registration trial , define ) Crohn 's Disease Activity Index ( CDAI ) &gt; 250 , ii ) Two follow : 1. elevate CReactive Protein ( CRP ) 2. endoscopic evidence active disease confirm histology 3. clear evidence active small bowel Crohn 's disease Computed tomography ( CT ) Magnetic Resonance ( MR ) enterography . 3 . Unsatisfactory course despite 3 immunosuppressive agent ( usually azathioprine , methotrexate infliximab , adalimumab and/or certolizumab ) addition corticosteroid . Patients relapse disease ( i.e . 1 exacerbation/year ) despite thiopurines , methotrexate and/or infliximab/adalimumab/certolizumab maintenance therapy clear demonstration intolerance / toxicity drug . 4 . Current problem unsuitable surgery patient risk develop short bowel syndrome . 5 . Informed consent : 1 . Prepared undergo additional study procedure per trial schedule 2 . Patient undergone intensive counseling risk 1 . Pregnancy unwillingness use adequate contraception study , woman childbearing age . Unwillingness use appropriate contraceptive measure male . 2 . Concomitant severe disease 1. renal : creatinine clearance &lt; 30 mL/min ( measure estimate ) 2. cardiac : clinical evidence refractory congestive heart failure ; leave ventricular ejection fraction &lt; 40 % multigated radionuclide angiography ( MUGA ) cardiac echo ; chronic atrial fibrillation necessitate oral anticoagulation ; uncontrolled ventricular arrhythmia ; pericardial effusion hemodynamic consequence evaluate experienced echo cardiographer . 3. pulmonary : diffusion capacity &lt; 40 % 4. psychiatric disorder include active drug alcohol abuse 5. concurrent recent history malignant disease ( exclude nonmelanoma skin cancer ) 6. uncontrolled hypertension , define rest systolic blood pressure ≥ 140 and/or rest diastolic pressure ≥ 90 despite least 2 antihypertensive agent . 7. uncontrolled acute chronic infection HIV , Human TLymphotropic virus ( HTLV1 2 ) , hepatitis virus infection investigator consider contraindication participation . 8. chronic disease cause significant organ failure . 3 . Infection risk thereof : 1 . Current clinical relevant abscess significant active infection . 2 . Perianal fistula without free drainage . Perianal fistulas exclusion provide natural free drainage seton suture ( ) place . 3 . History tuberculosis currently risk tuberculosis 4 . Quantiferon Gold test result investigation investigator regard evidence active tuberculosis . 5 . Abnormal chest Xray ( CXR ) consistent active infection neoplasm . 4 . Significant malnutrition : Body Mass Index ( BMI ) ≤ 18 , serum albumin &lt; 20g/l . 5 . Previous poor compliance . 6 . Concurrent enrollment protocol use investigational drug hematopoietic growth factor four week study entry .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>autologous</keyword>
	<keyword>Lymphoablation</keyword>
	<keyword>hematopoietic</keyword>
	<keyword>immune system</keyword>
</DOC>